Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2022

View Archived Issues

Nektar Therapeutics presents preclinical data on NKTR-255

KSHN-001034, a novel prodrug that delivers higher fulvestrant concentrations

BLU-222 shows efficacy in CCNE1-amplified ovarian cancer models

Chinese researchers divulge new compounds for cancer

New YAP1/TEAD interaction inhibitors disclosed by SpringWorks Therapeutics and collaborators

Humanwell Healthcare presents new P2X3 receptor antagonists

University of Texas System identifies CBP and/or p300 inhibitors

Medy-Tox patents new BTK inhibitors

Herantis reports blood-brain barrier penetration data with HER-096 in dogs

AT-0174 IDO/TDO dual inhibitor shows promise for treating platinum-resistant NSCLC

Allogeneic NK-cell therapy CAT-179 useful for controlling HER2-positive tumors

Study finds targets of T-cell response in multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...